IL-7受体在T细胞急性淋巴细胞白血病中频繁表达并预测JAK抑制剂敏感性
T-ALL中IL-7R(CD127)表达约70%,高于IL-7Rp突变约30%。原代异种移植体外数据显示,只要IL-7R表达,无论IL-7Rp突变状态如何,IL-7Rp均有功能,芦可替尼对表达者和突变者均损害T-ALL存活。表达者存在异位IL-7R表达和IL-7Rp成瘾,对芦可替尼更敏感;突变者对维奈克拉更敏感;两药联合在两组均呈协同效应。2例难治/复发T-ALL患者达完全缓解。
要点
- T-ALL中IL-7R(CD127)表达约70%,IL-7Rp突变约30%。
- 只要IL-7R表达,无论IL-7Rp突变状态如何,IL-7Rp均有功能。
- 芦可替尼联合维奈克拉在表达者和突变者中均呈协同效应。
核心结论
- IL7R表达可作为JAK抑制剂敏感性的生物标志物,使适合芦可替尼的T-ALL病例扩大至近约70%。
- 芦可替尼与维奈克拉联合在表达者和突变者中均呈协同效应,2例难治/复发T-ALL患者达完全缓解,为将该策略转化为临床作为桥接移植治疗提供概念验证。
研究设计与样本
- 研究比较了无IL-7R表达/IL-7Rp突变者(nonexpressers)、有IL7R表达但无IL-7Rp突变者(expressers)和IL-7Rp突变者(mutants)。
- 采用整合多组学分析,并使用原代来源异种移植进行体外(ex vivo)实验。
主要发现
- IL-7R(CD127)表达在T-ALL中约70%,较IL-7Rp突变约30%更常见。
- 整合多组学分析显示,几乎所有T-ALL亚型均存在IL-7R失调:无表达者在表观遗传水平、突变者在遗传水平、表达者在转录后水平。
- 原代来源异种移植体外数据显示,只要IL-7R表达,无论IL-7Rp突变状态如何,IL-7Rp均有功能。
- 芦可替尼在表达者和突变者中均损害T-ALL存活;表达者显示异位IL-7R表达和IL-7Rp成瘾,对芦可替尼敏感性更深;突变者对维奈克拉较表达者更敏感。
- 芦可替尼与维奈克拉联合在两组中均产生协同效应;2例难治/复发T-ALL患者达完全缓解。
关键数值与推荐
- IL-7R(CD127)表达约70%,IL-7Rp突变约30%。
- 芦可替尼联合维奈克拉在表达者和突变者中均呈协同效应。
- 2例难治/复发T-ALL患者经联合治疗达完全缓解。
临床怎么用
- IL7R表达可作为JAK抑制剂敏感性的生物标志物,使适合芦可替尼的T-ALL病例扩大至近约70%。
- 作者提供概念验证,支持将该策略转化为临床作为桥接移植治疗。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
T-cell acute lymphoblastic leukemia (T-ALL) is an aggressive hematological malignancy with a dismal prognosis related to refractory/relapsing diseases, raising the need for new targeted therapies. Activating mutations of interleukin-7-receptor pathway genes (IL-7Rp) play a proven leukemia-supportive role in T-ALL. JAK inhibitors, such as ruxolitinib, have recently demonstrated preclinical efficacy. However, prediction markers for sensitivity to JAK inhibitors are still lacking. Herein, we show that IL-7R (CD127) expression is more frequent (∼70%) than IL-7Rp mutations in T-ALL (∼30%). We compared the so-called nonexpressers (no IL-7R expression/IL-7Rp mutation), expressers (IL7R expression without IL-7Rp mutation), and mutants (IL-7Rp mutations). Integrative multiomics analysis outlined IL-7R deregulation in virtually all T-ALL subtypes, at the epigenetic level in nonexpressers, genetic level in mutants, and posttranscriptional level in expressers. Ex vivo data using primary-derived xenografts support that IL-7Rp is functional whenever the IL-7R is expressed, regardless of the IL-7Rp mutational status. Consequently, ruxolitinib impaired T-ALL survival in both expressers and mutants. Interestingly, we show that expressers displayed ectopic IL-7R expression and IL-7Rp addiction conferring a deeper sensitivity to ruxolitinib. Conversely, mutants were more sensitive to venetoclax than expressers. Overall, the combination of ruxolitinib and venetoclax resulted in synergistic effects in both groups. We illustrate the clinical relevance of this association by reporting the achievement of complete remission in 2 patients with refractory/relapsed T-ALL. This provides proof of concept for translation of this strategy into clinics as a bridge-to-transplantation therapy. IL7R expression can be used as a biomarker for sensitivity to JAK inhibition, thereby expanding the fraction of patients with T-ALL eligible for ruxolitinib up to nearly ∼70% of T-ALL cases.
引用
- Courtois L, Cabannes-Hamy A, Kim R, et al. IL-7 receptor expression is frequent in T-cell acute lymphoblastic leukemia and predicts sensitivity to JAK inhibition. Blood. 2023. PMID: 37023368. doi:10.1182/blood.2022017948
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。